Wednesday, December 21, 2016


 


The University of Chicago Celiac Disease Center is a premier research center for celiac disease in the United States and the world.  I received an article in my email about their a little bit of the research they are doing and what they are starting to find out. The more research we can get the more likely there could be a cure.

RESEARCH IN PROGRESS...
1. Evidence that viral infections play a role in celiac disease. The prevalence of celiac disease continues to rise, suggesting that environmental factors must trigger and precipitate the disease. For a long time, it was suspected that viruses might play a role in celiac disease, and more generally in autoimmunity. Thanks to generous donations, we were able to initiate studies and obtain preliminary data that were critical for receiving NIH funding to study the role of intestinal viruses in celiac disease pathogenesis in collaboration with Drs. Terrence Dermody (University of Pittsburgh) and Ramnik Xavier (Massachusetts General Hospital and Broad Institute). We now have a manuscript under revision showing that viruses can disrupt tolerance to gluten and promote inflammatory immune responses and transglutaminase activation. Furthermore, our study defines the mechanistic basis for how viruses can disrupt tolerance to gluten and initiate celiac disease. This study will help define vaccine strategies targeting viruses that have the potential to trigger celiac disease, and hence may help prevent disease in at-risk children with a family history of celiac disease.

2. Initiation of a clinical trial testing the ability of Montelukast, an FDA-approved drug for asthma that blocks cysteinyl leukotrienes, to prevent tissue damage in celiac disease patients eating gluten. Our publication in the high impact Journal of Experimental Medicine, with News & Views, reveals that the lipid signaling molecules cysteinyl leukotrienes are highly increased in celiac disease and are involved in tissue destruction. Based on this publication, Dr. Sonia Kupfer was able to obtain approval for and launch a clinical trial at the University of Chicago aimed at assessing the therapeutic potential of Montelukast in adult celiac disease patients.

3. Completion of a clinical trial in celiac disease patients who do not respond to a gluten-free diet. There is currently no effective treatment for refractory celiac disease. Based on encouraging results, we are finalizing the enrollment of patients with refractory celiac disease in a clinical trial testing the efficacy of a drug blocking the cytokine IL-15, which we have identified as playing a critical role in celiac disease. This trial is sponsored by the NIH and conducted in collaboration with Professor Thomas Waldmann (NIH/NCI) and Professor Joseph Murray (Mayo Clinic). Our goal is to complete the trial by the end of 2017 and analyze and publish the results in 2018.

4. Discovery of an important mechanism underlying the development of a disease-promoting microbiota in celiac disease. Our body harbors more than 40 trillion microbial cells. These microbes play an important role in our health. However, under certain circumstances, deleterious microbes outgrow good microbes and prevent them from exerting their beneficial effects. We unexpectedly found that IL-15, the stress-induced cytokine overexpressed in celiac disease patients, alters the microbiota and prevents expression of butyrate, a health-promoting short chain fatty acid. This result was published this year in ISME Journal, a highly regarded multidisciplinary journal of microbial ecology. We are further analyzing the impact of these microbial alterations and are assessing ways to revert the deleterious effect of IL-15 on the microbiota.

5. Generating relevant mouse models for celiac disease. The lack of a relevant mouse model of celiac disease has been a major limitation in the field of celiac disease. Such preclinical models are essential to test new therapeutic avenues. We now have developed the first relevant mouse model of celiac disease where mice expressing the human celiac disease-predisposing HLA molecule develop anti-gluten antibodies, anti-tissue transglutaminase 2 antibodies and villous atrophy upon eating gluten. We are currently using this preclinical mouse model to determine whether inhibitors of tissue transglutaminase-2 developed by our collaborator Dr. Chaitan Khosla (an internationally renowned chemist at Stanford University) can prevent celiac disease. If successful, this study will provide strong support for initiating clinical trials testing inhibitors of tissue transglutaminase-2 in celiac disease patients.

 Click Here read the article.
If you would like to donate or find out more information click here.

Tuesday, December 20, 2016

Funny Elf on the Shelf Videos

I hope you all are having a wonderful holiday season. I am excited to show you a cute Naughty Elf on the Shelf series I created.  An Elf on the Shelf episodes will be coming out Tuesday and Thursday until the Holiday season ends.  My channel doesn't just do Elf on the Shelf, we do other comedy skits, gluten-free cooking, vlogs and a variety show, so make sure to subscribe to my youtube channel Entertainment For All Network.  CLICK HERE  . Thanks!


Naughty Elf on the Shelf Ruins Christmas Tree- Episode 2

Naughty Elf on the Shelf Makes Homemade Shocking Garland- Episode 3


Naughty Elf on the Shelf's Candy Addiction- Episode 4




Monday, June 13, 2016

Gluten Free Subscription Boxes

Click Here to Join:
Send Me Gluten Free: Gluten Free Subscription Box

What is my favorite Gluten-Free subscription box?
My favorite is Send Me Gluten-Free. Most of the boxes I received from them have more than two full-size product in it. The other subscription boxes usually only have one and then a bunch of tiny size samples.











Click Here to Join:
Send Me Gluten Free: Gluten Free Subscription Box

LYING NEXT TO ME by Gregg Olsen Nerd Book Blast and Giveaway

SYNOPSIS No matter what you see, no matter what you’ve heard, assume nothing. Adam and Sophi e Warner and their three-year-old dau...